. 2013 Oct 29;7:269–277. doi: 10.4137/CMO.S10594

Table 3.

Summary of phase III trials of axitinib in treatment of RCC.

References	Trial	Setting	N	Drug	PFS (months)	P	ORR (%)	P	OS (months)
Rini et al¹⁸	AXIS	2nd line	723	Axitinib	6.4	<0.0001	19.4	0.0001	20.1
				Sorafenib	5.0		9.4		19.2
Hutson et al¹⁹	AGILE	1st line	288	Axitinib	10.1	NS	32.3	0.0006	NA
				Sorafenib	6.5		14.6